ADC Therapeutics (ADCT)
(Delayed Data from NYSE)
$2.64 USD
-0.12 (-4.35%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.63 -0.01 (-0.38%) 6:22 PM ET
2-Buy of 5 2
F Value F Growth B Momentum F VGM
Fundamental Charts
About Market Cap
As of the previous market close, ADC Therapeutics SA has a market cap of $273.73M, which represents its share price of $2.76 multiplied by its outstanding shares number of 99.18M. As a small-cap company, ADCT's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ADCT 2.64 -0.12(-4.35%)
Will ADCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADCT
Are Medical Stocks Lagging ADC Therapeutics (ADCT) This Year?
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Zymeworks Inc. (ZYME) Reports Q1 Loss, Tops Revenue Estimates
Kura Oncology (KURA) Reports Q1 Loss, Lags Revenue Estimates
AC Immune (ACIU) Reports Q1 Loss, Lags Revenue Estimates
Other News for ADCT
ADC Therapeutics to Host Second Quarter 2025 Financial Results Conference Call on August 12, ...
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan | ADCT Stock News
ADC Therapeutics Makes Grant to New Employee Under Inducement Plan | ADCT Stock News
ADC Therapeutics (ADCT) Files Prospectus for Share Sale
ADC Therapeutics files to sell 27.73M common shares by selling shareholders